ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 02/28/23

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The complement system is a part of the body's immune system. According to the company ARO...

- Achieved Mean Reductions of 88% in C3 and 91% in AH50 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed...

Summary Arrowhead Pharmaceuticals, Inc. is a company with strong potential. However, it has yet to conclusively prove the worth of any part of its vast pipeline. I will stick to the sideline on Arrowhead Pharmaceuticals, Inc. until that happens. In my previous coverage ...

Johnson & Johnson's ( NYSE: JNJ ) Janssen unit has relinquished rights to a RNAi candidate for non-alcoholic steatohepatitis ( NASH ), returning rights to Arrowhead Pharmaceuticals ( NASDAQ: ARWR ). The candidate, ARO-PNPLA3 (formerly JNJ-75220795), is an RNAi therapeu...

- Achieved Up to 40% Mean Reduction in Liver Fat in PNPLA3 I148M Homozygotes After Single-Dose Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option ag...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2023 Earnings Conference Call February 6, 2023 16:30 ET Company Participants Vincent Anzalone - Vice President, Investor Relations Christopher Anzalone - President and Chief Executive Officer Javier San Martin - Chief Medical O...

Arrowhead Pharmaceuticals' ( NASDAQ: ARWR ) 128% year-over-year increase in revenue in fiscal 2023 Q1 is due in part to  milestone payments from Amgen ( AMGN ) and Horizon Therapeutics ( HZNP ). The company recorded ~$62.6M in revenue in the quarter. In October 2022, ...

Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): Q1 EPS of -$0.39 may not be comparable to consensus of $0.13. Revenue of $62.55M (+128.3% Y/Y). For further details see: Arrowhead PharmaceuticalsEPS of -$0.39, revenue of $62.55M

- Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022. The company is hosting a conference call today, February 6, 2023, at 4:30 p.m. ET to...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) fell sharply on Monday after Cantor Fitzgerald saw risks to the company's licensing deal with Johnson & Johnson ( NYSE: JNJ ), noting that the pharma giant is reportedly deprioritizing its portfolio targeted at hepatitis virus. Ac...